SAN DIEGO, June 28, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an
oncology company focused on the clinical development of novel
therapeutics targeting cancer metabolism, announced today that it
will change its name to MEI Pharma, Inc. and its common stock will
begin trading under the new ticker symbol MEIP when the market
opens on Monday, July 2, 2012.
(Logo:
http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)
"Over the past two years we have successfully relocated our
headquarters to the U.S., acquired a robust intellectual property
portfolio, assembled world-class drug development expertise and
advanced our two most promising oncology candidates into clinical
trials," said Daniel P. Gold, Ph.D.,
President and Chief Executive Officer of Marshall Edwards. "Now, with our drug candidates
poised for the next phase of clinical development and our company
in a position for growth, it is time for a name that reflects our
identity and more effectively conveys our purpose."
The Company's common stock will be assigned a new CUSIP number
of 55279B103 in connection with the name change. Outstanding stock
certificates will not be affected and will not need to be
exchanged.
About MEI Pharma
MEI Pharma, Inc. is a San
Diego-based oncology company focused on the clinical
development of novel therapeutics targeting cancer metabolism. The
Company's lead drug candidates, ME-143 and ME-344, have been shown
in laboratory studies to interact with specific enzyme targets
resulting in inhibition of tumor cell metabolism, a function
critical for cancer cell survival. Marshall
Edwards presented safety and pharmacokinetic data from a
Phase I clinical trial of intravenous ME-143 in patients with solid
refractory tumors at the American Society of Clinical Oncology
Annual Meeting in June 2012. The
Company received approval of its IND application for ME-344 in
April 2012 and a Phase I clinical
trial of intravenous ME-344 in patients with solid refractory
tumors is ongoing. For more information, go to
www.marshalledwardsinc.com until July 1,
2012, thereafter www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical trials and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
SOURCE Marshall Edwards, Inc.